Foundry Partners LLC Has $10.73 Million Stock Holdings in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Foundry Partners LLC lifted its position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 1,597.3% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 86,429 shares of the specialty pharmaceutical company's stock after purchasing an additional 81,337 shares during the quarter. Foundry Partners LLC owned 0.14% of Jazz Pharmaceuticals worth $10,730,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the company. Quadrant Capital Group LLC raised its stake in Jazz Pharmaceuticals by 97.1% during the fourth quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company's stock worth $25,000 after acquiring an additional 101 shares in the last quarter. Elequin Capital LP raised its stake in Jazz Pharmaceuticals by 677.8% during the fourth quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company's stock worth $26,000 after acquiring an additional 183 shares in the last quarter. CoreFirst Bank & Trust acquired a new position in Jazz Pharmaceuticals during the fourth quarter worth $28,000. Allianz SE acquired a new position in Jazz Pharmaceuticals during the fourth quarter worth $29,000. Finally, Parallel Advisors LLC raised its stake in Jazz Pharmaceuticals by 85.6% during the first quarter. Parallel Advisors LLC now owns 258 shares of the specialty pharmaceutical company's stock worth $32,000 after acquiring an additional 119 shares in the last quarter. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Jazz Pharmaceuticals

In other news, CEO Bruce C. Cozadd sold 1,000 shares of the firm's stock in a transaction dated Tuesday, July 1st. The stock was sold at an average price of $107.63, for a total transaction of $107,630.00. Following the sale, the chief executive officer owned 436,973 shares of the company's stock, valued at $47,031,403.99. This trade represents a 0.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Seamus Mulligan purchased 1,621 shares of the company's stock in a transaction dated Monday, May 12th. The shares were acquired at an average cost of $103.00 per share, for a total transaction of $166,963.00. Following the transaction, the director owned 101,621 shares of the company's stock, valued at $10,466,963. This trade represents a 1.62% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders have sold 2,500 shares of company stock worth $277,930. 4.30% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on JAZZ shares. Needham & Company LLC reiterated a "buy" rating and set a $202.00 price objective on shares of Jazz Pharmaceuticals in a research note on Wednesday, June 11th. Piper Sandler restated an "overweight" rating and set a $147.00 target price (down previously from $176.00) on shares of Jazz Pharmaceuticals in a report on Wednesday, May 7th. Robert W. Baird decreased their target price on Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating on the stock in a report on Wednesday, May 7th. Deutsche Bank Aktiengesellschaft assumed coverage on Jazz Pharmaceuticals in a report on Tuesday, July 15th. They set a "buy" rating and a $152.00 target price on the stock. Finally, Wall Street Zen cut Jazz Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 15th. Two equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $181.64.

Jazz Pharmaceuticals Trading Up 3.3%

NASDAQ:JAZZ traded up $3.69 during mid-day trading on Tuesday, hitting $116.34. The company had a trading volume of 967,302 shares, compared to its average volume of 834,907. Jazz Pharmaceuticals PLC has a fifty-two week low of $95.49 and a fifty-two week high of $148.06. The business's fifty day moving average is $109.31 and its two-hundred day moving average is $118.15. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.97 and a current ratio of 3.38. The firm has a market cap of $7.04 billion, a P/E ratio of 15.51, a P/E/G ratio of 5.63 and a beta of 0.32.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last released its earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share for the quarter, missing the consensus estimate of $4.65 by ($2.97). The company had revenue of $897.84 million during the quarter, compared to analyst estimates of $984.16 million. Jazz Pharmaceuticals had a net margin of 11.86% and a return on equity of 26.62%. The company's quarterly revenue was down .5% compared to the same quarter last year. During the same period in the previous year, the company posted $2.68 EPS. As a group, research analysts expect that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current year.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.